SCHEMBL6723592

SCHEMBL6723592

CN(c1ccccc1)c1ccccc1-c1ccccc1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.40
CES1 P23141 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GSK3B P49841 1/20 0.39
PDE5A O76074 2/20 0.38
PTGS2 P35354 1/20 0.37
HTR7 P34969 2/20 0.37
ALDH1A1 P00352 4/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
EGFR P00533 1/20 0.36
SRC P12931 1/20 0.36
HSD17B10 Q99714 2/20 0.35
HPGD P15428 1/20 0.35
BCL2L1 Q07817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723800 0.92 PTGS2 (0.39) PTPN1CES1MEN1KMT2ASMN1; SMN2
SCHEMBL6724358 0.92 PTGS2 (0.39) PTPN1CES1MEN1KMT2ASMN1; SMN2
SCHEMBL6723411 0.92 PTPN1 (0.42) PTPN1CES1MEN1KMT2ASMN1; SMN2
SCHEMBL27498154 0.90 PTPN1 (0.41) PTPN1CES1MEN1KMT2ASMN1; SMN2
SCHEMBL6723956 0.90 MEN1 (0.42) MEN1KMT2ASMN1; SMN2PTGS2HTR7
SCHEMBL6723582 0.88 CHKA (0.41) PTPN1CES1MEN1KMT2ASMN1; SMN2
SCHEMBL21320353 0.88 GSK3B (0.46) PTPN1CES1SMN1; SMN2GSK3BPTGS2
SCHEMBL6724496 0.85 MEN1 (0.38) MEN1KMT2ASMN1; SMN2PTGS2HTR7
SCHEMBL279361 0.85 ALDH1A1 (0.41) PTPN1CES1MEN1KMT2ASMN1; SMN2
SCHEMBL6723824 0.84 TAAR1 (0.39) PTPN1CES1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178216-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-15 US disclosed
US-8178216-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-15 US disclosed
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-03-19 US disclosed
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative CRY1, GRK1, CRY2 PTPN1 2795/4885CES1 1658/4885MEN1 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.